55.59
price up icon2.77%   1.50
after-market アフターアワーズ: 56.25 0.66 +1.19%
loading
前日終値:
$54.09
開ける:
$54.61
24時間の取引高:
1.95M
Relative Volume:
0.79
時価総額:
$10.69B
収益:
$2.95B
当期純損益:
$523.88M
株価収益率:
20.67
EPS:
2.69
ネットキャッシュフロー:
$620.18M
1週間 パフォーマンス:
+0.29%
1か月 パフォーマンス:
-9.52%
6か月 パフォーマンス:
+5.64%
1年 パフォーマンス:
-22.28%
1日の値動き範囲:
Value
$54.61
$55.73
1週間の範囲:
Value
$53.35
$55.89
52週間の値動き範囲:
Value
$50.76
$73.18

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1114)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,221
Name
Twitter
Name
次回の収益日
2026-02-23
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ALNY, ARGX, INSM

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BMRN icon
BMRN
Biomarin Pharmaceutical Inc
55.59 10.40B 2.95B 523.88M 620.18M 2.69
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 113.96B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 78.41B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 40.85B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 42.05B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 29.99B 606.42M -1.28B -997.58M -6.403

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-01-28 再開されました Barclays Overweight
2026-01-20 アップグレード Canaccord Genuity Hold → Buy
2025-12-03 ダウングレード Leerink Partners Outperform → Market Perform
2025-11-06 ダウングレード Stifel Buy → Hold
2025-09-08 開始されました H.C. Wainwright Neutral
2025-09-03 開始されました Raymond James Outperform
2025-07-03 再開されました Morgan Stanley Overweight
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
Mar 25, 2026

BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo! Finance Canada

Mar 25, 2026
pulisher
Mar 25, 2026

Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 25, 2026
pulisher
Mar 24, 2026

Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 24, 2026
pulisher
Mar 22, 2026

BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN

Mar 22, 2026
pulisher
Mar 21, 2026

RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026
pulisher
Mar 21, 2026

BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN

Mar 21, 2026
pulisher
Mar 20, 2026

Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance

Mar 20, 2026
pulisher
Mar 20, 2026

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool

Mar 20, 2026
pulisher
Mar 20, 2026

BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO - MSN

Mar 20, 2026
pulisher
Mar 20, 2026

Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga

Mar 20, 2026
pulisher
Mar 19, 2026

BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan

Mar 19, 2026
pulisher
Mar 19, 2026

Hudson Bay Capital Management LP Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 19, 2026
pulisher
Mar 18, 2026

BioMarin (BMRN) EVP Hubbard receives stock awards and withholds shares for tax - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

BioMarin (NASDAQ: BMRN) EVP granted stock, options and covers tax with shares - Stock Titan

Mar 18, 2026
pulisher
Mar 18, 2026

BioMarin-Backed ENERGY 2 Trial Targets High-Value Niche in Ultra-Rare Infant Disease - TipRanks

Mar 18, 2026
pulisher
Mar 18, 2026

BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO - Insider Monkey

Mar 18, 2026
pulisher
Mar 18, 2026

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail

Mar 18, 2026
pulisher
Mar 18, 2026

What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

Form 4 Biomarin Pharmaceutical Inc For: 17 March By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 17, 2026

BioMarin (BMRN) legal chief receives options, RSUs and tax withholding - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

BioMarin (NASDAQ: BMRN) CFO gets stock grants and tax share withholding - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

BioMarin (BMRN) CEO granted 89,200 options and 62,440 RSUs in 2026 awards - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Price-Driven Insight from (BMRN) for Rule-Based Strategy - Stock Traders Daily

Mar 17, 2026
pulisher
Mar 17, 2026

A Look At BioMarin Pharmaceutical (BMRN) Valuation After A Year Of Softer Share Price Momentum - Sahm

Mar 17, 2026
pulisher
Mar 16, 2026

Wolfe Research Maintains Outperform on BioMarin (BMRN) March 16, 2026 - Meyka

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin Pharmaceutical Inc. 8-K Filing: Company Information, Address, and Stock Details (March 16, 2026) - Minichart

Mar 16, 2026
pulisher
Mar 16, 2026

Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) - MSN

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap DownTime to Sell? - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma

Mar 16, 2026
pulisher
Mar 16, 2026

Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com - Investing.com India

Mar 16, 2026
pulisher
Mar 16, 2026

Wolfe Research reiterates Outperform on BioMarin stock at $95 - Investing.com

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin stops mid-stage trials of bone disorder treatment - Reuters

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials - TipRanks

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ) - Seeking Alpha

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin (NASDAQ: BMRN) stops VOXZOGO trials in Turner, SHOX and ACAN - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Biomarin Pharmaceutical Inc Announces Discontinuation of Dosing and Enrollment in Phase 2 Trials for Voxzogo in Turner Syndrome, Shox-Deficiency and Aggrecan-Deficiency - marketscreener.com

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin Pharmaceutical Stock (ISIN: US09061G1013) Gains Momentum on Voxzogo Data and $4.7B Amicus A - AD HOC NEWS

Mar 16, 2026
pulisher
Mar 16, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case - ChartMill

Mar 16, 2026
pulisher
Mar 15, 2026

BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com Nigeria

Mar 15, 2026
pulisher
Mar 15, 2026

BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 15, 2026
pulisher
Mar 15, 2026

Braidwell LP Acquires Shares of 528,000 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Boone Capital Management LLC Sells 118,903 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 15, 2026
pulisher
Mar 15, 2026

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness - simplywall.st

Mar 15, 2026
pulisher
Mar 15, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 15, 2026
pulisher
Mar 14, 2026

Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - Sahm

Mar 14, 2026
pulisher
Mar 14, 2026

BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN

Mar 14, 2026
pulisher
Mar 14, 2026

BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Yahoo Finance

Mar 14, 2026

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
大文字化:     |  ボリューム (24 時間):